Ligand Pharmaceuticals Incorporated
LGND evidence brief
What we can confirm
- BioSniper Score:
- 3.6 / 10
- Market Cap:
- $6.04B
What it means
What to watch
Prepared research question
What matters most for LGND—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LGND
Ligand Pharmaceuticals is a biopharmaceutical royalty company that deploys capital and licenses technologies to acquire diversified royalty streams from mid- to late-stage and commercial products, generating non-dilutive cash flows through a lean operating model [sec · filed 2026-04-21].
Key risk: Partner dependency
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$6.04B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Ligand Pharmaceuticals is a biopharmaceutical royalty company that deploys capital and licenses technologies to acquire diversified royalty streams from mid- to late-stage and commercial products, generating non-dilutive cash flows through a lean operating model [sec · filed 2026-04-21].
- As of 2026-06-30, Ligand reported cash & equivalents of $1,006.7M, total revenue of $63.7M, net income of $48.5M, shareholders' equity of $967.5M, and total debt of $1,160.0M [sec].
- Ligand's business model focuses on deploying capital through royalty purchases, development-stage financing, and acquisitions to create cash-flowing royalties while mitigating binary drug-development risk [sec · filed 2026-04-21].
- The company operates two infrastructure-light royalty-generating IP platforms: Captisol (optimizes drug solubility/stability) and NITRICIL (enables tunable drug release) [sec_mda · as of 2026-05-08].
- In 2025, Ligand invested $131 million and added 10 new programs to its portfolio, exceeding its business development targets [sec · filed 2026-04-21].
- Following the XOMA Acquisition, Ligand's portfolio now comprises over 200 commercial, clinical, and preclinical stage royalty assets [sec_mda · as of 2026-08-07].
What works
- Ligand's lean corporate cost structure and focus on non-dilutive cash flows from royalties reduce the capital intensity and binary risk of traditional drug development [sec · filed 2026-04-21].
- The company has established alliances with leading biopharmaceutical firms including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter [sec_mda · as of 2026-05-08].
- Ligand's portfolio has more than doubled to over 200 assets through the XOMA Acquisition, providing broad diversification across commercial, clinical, and preclinical stages [sec_mda · as of 2026-08-07].
- Full-year 2025 adjusted EPS exceeded original guidance by more than 30%, reflecting strong financial performance [sec · filed 2026-04-21].
What to weigh
- Ligand's revenue is heavily reliant on collaborative partners for milestone payments, royalties, and contract payments, creating dependency on partner performance [sec · filed 2026-05-18].
- The company carries significant total debt of $1,160.0M as of 2026-06-30, which may increase financial risk [sec].
- Drug development and commercialization involve inherent uncertainties, including regulatory changes, tariff policies, and market conditions that could affect royalty streams [sec · filed 2026-05-18].
- Ligand's special situations strategy, such as the Pelthos spin-out, requires significant effort and may not always yield superior returns [sec · filed 2026-04-21].
From the filings
Quoted directly from source documents.
Ligand's business model is based on deploying capital and licensing technologies to acquire royalty streams.
“We are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines.”
SEC filings · April 21, 2026
Ligand's portfolio now includes over 200 royalty assets after the XOMA Acquisition.
“our portfolio has more than doubled in size, now comprising over 200 commercial, clinical, and preclinical stage royalty assets.”
SEC MD&A · August 7, 2026
Ligand has alliances with major biopharmaceutical companies.
“We have established multiple alliances, licenses and other business relationships with the world's leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter.”
SEC MD&A · May 8, 2026
Ligand's 2025 adjusted EPS exceeded original guidance by more than 30%.
“We delivered exceptional financial performance, with full-year adjusted EPS 1 exceeding our original 2025 guidance by more than 30%.”
SEC filings · April 21, 2026
Risks & what to watch (4)›
Key risks
- Partner dependency — Revenue relies on partners for milestones, royalties, and payments; partner underperformance could reduce cash flows [sec · filed 2026-05-18].
- High debt level — Total debt of $1,160.0M as of 2026-06-30 may strain finances if cash flows decline [sec].
- Drug development risk — Inherent uncertainties in drug development, regulatory changes, and market conditions can affect royalty streams [sec · filed 2026-05-18].
- Special situations effort — Complex transactions like the Pelthos spin-out require significant effort and may not always yield superior returns [sec · filed 2026-04-21].
What to watch
- Progress of the ROBBIN Phase 3 trial for MSS colon cancer, with first dosing expected in Q1 2027 [sec_mda · as of 2026-08-07].
- Commercial ramp of Zelsuvmi and associated milestone payments, including a 13% royalty on worldwide sales [sec · filed 2026-04-21].
- Integration and performance of the over 200 royalty assets from the XOMA Acquisition [sec_mda · as of 2026-08-07].
- Ligand's ability to deploy the planned $150–200 million in high-quality investment opportunities to sustain pipeline growth [sec · filed 2026-04-21].
Sources: SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Ligand Pharmaceuticals Incorporated through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ligand Pharmaceuticals Incorporated facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 1.26 · 9% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 50 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
353
Total value held
$4.07B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,961,923 | $591.3M |
| vanguard portfolio management llc | 1,100,267 | $219.7M |
| janus henderson group plc | 1,009,891 | $201.6M |
| vanguard capital management llc | 848,089 | $169.3M |
| invesco ltd. | 823,604 | $164.4M |
| state street corp | 778,856 | $155.5M |
| fmr llc | 596,127 | $119.0M |
| nomura asset management international inc. | 573,312 | $114.5M |
| franklin resources inc | 573,177 | $114.4M |
| chicago capital, llc | 561,675 | $112.1M |
Showing top 10 of 353 institutional holders of Ligand Pharmaceuticals Incorporated. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 8.7%
- Days to cover
- 6.5
- Shares short
- 1,455,087
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LGND short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals is a biopharmaceutical royalty company that deploys capital and licenses technologies to acquire diversified royalty streams from mid- to late-stage and commercial products, generating non-dilutive cash flows through a lean operating model [sec · filed 2026-04-21].
Who is the CEO of Ligand Pharmaceuticals Incorporated?
Mr. Todd C. Davis Ph.D. is the chief executive officer of Ligand Pharmaceuticals Incorporated (LGND).
Where is Ligand Pharmaceuticals Incorporated headquartered?
Ligand Pharmaceuticals Incorporated (LGND) is headquartered in Jupiter, FL, United States.
What therapeutic areas does Ligand Pharmaceuticals Incorporated focus on?
Ligand Pharmaceuticals Incorporated develops therapies across Neurology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.